4. Blood biomarkers to be validated for their diagnostic potential in endometriosis.

Blood biomarkers 1	Replacement test	SnOUT triage test	SpIN triage test
1. Angiogenesis and growth markers
VEGF > 680 pg/ml	±	±	+
VEGF > 236 pg/ml	±	±
2. High‐throughput markers
Metabolome by ESI‐MS/MS (SMOH C16:1 + PCaa C36:2/PCae C34:2)		±
Proteome by SELDI‐TOF‐MS (6 peaks with molecular weights of 1.63, 3.05, 3.53, 3.77, 5.05 and 5,07 Da)			+
3. Immune system and inflammatory markers
IL‐6 > 12.2 pg/ml	+	+
4. Oxidative stress markers
PON‐1 < 141.5 U/l	+	+
Carbonyls < 14.9 μM		±
5. Post‐transcriptional regulators of gene expression (microRNAs)
miR‐9*			+
miR‐141*			+
miR‐145*			+
miR‐20a < 0.69			±
miR‐22 < 0.56	±	±
miR‐532‐3p			±
6. Tumour markers
CA‐125 (cut‐off value > 43 U/ml)	+	+
7. Combined blood tests
IL‐6 > 12.2 pg/ml + TNF‐α > 12.45 pg/ml			+
IL‐6 > 12.2 pg/ml + CRP > 438 μg/ml			+
TNF‐α > 12.45 pg/ml + CRP > 438 μg/ml			+
miR‐199a + miR‐542‐3p	+	+
CA‐125 + STX‐5 + LN‐1	±	+
IL‐6 > 12.2 pg/ml + TNF‐α > 12.45 pg/ml + CRP > 438 μg/ml			+
miR‐199a + miR‐122 + miR‐145* + miR‐542‐3p	±	±	+
CA‐125 > 17.6 IU/ml + VEGF > 236 pg/ml			±
CA‐125 + CA‐19‐9 + survivin			±
CA‐125 > 50 IU/ml +/or CCR1 > 1.16 +/or MCP‐1 > 140 pg/ml	±	±
CA‐125 > 20 IU/ml + MCP‐1 > 152.744 pg/ml + leptin > 3.14 ng/ml			±
CA‐125 + IL‐8 + TNF‐α		±
CA‐125 + CA‐19.9 + IL‐6 + IL‐8 + TNF‐α + hs‐CRP (in menstrual phase of the cycle)	±	±
8. Tests that specifically differentiate endometrioma from other benign ovarian cysts in women of reproductive age
Urocortin > 29 pg/ml	+	+
Urocortin > 33 pg/ml			±
Follistatin > 1433 pg/ml	±	±	±
CA‐125 > 30 U/ml and > 36 U/ml			+
CA‐125 ≥ 25 U/ml + CA‐19.9 ≥ 22 U/ml			±
Notes: + meets the criteria Replacement test: sensitivity ≥ 94 and specificity ≥ 79 SnOUT triage test: sensitivity ≥ 95 and specificity ≥ 50 SpIN triage test: sensitivity ≥ 50 and specificity ≥ 95 ± approaches the criteria (within 5% of the pre‐defined criteria)

¹ This group included: tests with an adequate diagnostic performance, but insufficient data to confidently comment on their diagnostic role (less than 3 studies with the diagnostic estimates meeting the criteria for either a replacement or triage test); and tests where the diagnostic estimates were approaching the criteria for replacement or triage tests in a small number of studies, and it is possible that they would reach this criteria if further studies were performed (less than 3 studies with the diagnostic estimates within 5% of the criteria for either replacement or triage tests).

For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.